IP Library › Granted Patent US 12,436,145
Granted Patent B2
US 12,436,145 · App. 17/100,005 · Granted Oct 7, 2025

Cryptic antibiotics and methods for detecting bioactive cryptic metabolites

Inventors: Mohammad R. Seyedsayamdost (Princeton, NJ); Kyuho Moon (Princeton, NJ)
Assignee: The Trustees of Princeton University
G01N33/4833C12N1/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,436,145
App. No.
17/100,005
Granted
Oct 7, 2025
Kind
B2
Abstract

Bacteria harbor an immense reservoir of potentially new and therapeutic small molecules in the form of “silent” biosynthetic gene clusters. These clusters can be identified bioinformatically but are at best sparingly expressed under normal laboratory growth conditions; their products are therefore not interrogated during bioactivity screening exercises. An estimated 80-90% of biosynthetic loci are silent, meaning that routine bioactivity screens miss the majority of microbial biosynthetic potential. Disclosed herein is a method that allows access to this vast hidden metabolome, thereby allowing researchers to screen the complete metabolomes of microorganisms in the search of new therapeutic leads. The disclosed approach, “Bioactivity-HiTES”, broadly activates the secondary metabolomes of bacteria and links the cryptic metabolites produced to a desired biological activity. Using the disclosed method, induction of cryptic antibiotics was detected in all four actinomycete bacterial strains that were tested as proof-of-concept. Follow-up in two cases demonstrated the production of two new antibiotics: In one case, the taylorflavins, pyrimidine antibiotics that harbor selective growth-inhibitory activity toward Gram-negative bacteria, were identified. For example, taylorflavin B shows potent minimal inhibitory concentration toward Neisseria gonorrhoeae and Acinetobacter baumanii , but not against a panel of Gram-positive bacteria. In the second case, the lanthipeptide cebulantin, which is specific toward Gram-negative Vibrio pathogens, but does not affect the growth of Gram-positive bacteria tested, was identified. These compounds, taylorflavins and cebulantin, may serve as useful leads in the future. At the same time, Bioactivity-HiTES may be applied broadly to identify cryptic metabolites with the desired biological properties.

Claims (16)

1. A method for inhibiting growth of a Gram-negative pathogen, comprising:

providing a composition comprising a first antimicrobial agent to a location containing a Gram-negative pathogen, the first antimicrobial agent comprising taylorflavin A, or cebulantin, and

allowing the first antimicrobial agent to come into contact with the Gram-negative pathogen,

wherein either:

the Gram-negative pathogen is P. aeruginosa or E. coli and the first antimicrobial agent is taylorflavin A, or

the Gram-negative pathogen is E. coli, V. parahaemolyticus, V. cholerae, V. ordalii, V. anguillarum , or P. aeruginosa and the first antimicrobial agent is cebulantin.

2. The method according to claim 1 , wherein the composition further comprises a second antimicrobial agent different from the first antimicrobial agent.

3. The method according to claim 1 , wherein the composition further comprises a pharmaceutical agent.

4. The method of claim 1 , wherein the Gram-negative pathogen is P. aeruginosa and the first antimicrobial agent is taylorflavin A with a concentration of 25 μg/mL.

5. The method of claim 1 , wherein the Gram-negative pathogen is E. coli and the first antimicrobial agent is taylorflavin A with a concentration of 37.5 μg/mL.

6. The method of claim 1 , wherein the Gram-negative pathogen is E. coli and the first antimicrobial agent is cebulantin with a concentration of 9.7±0.4 μM.

7. The method of claim 1 , wherein the Gram-negative pathogen is V. parahaemolyticus and the first antimicrobial agent is cebulantin with a concentration of 8.8±2.1 μM.

8. The method of claim 1 , wherein the Gram-negative pathogen is V. cholerae and the first antimicrobial agent is cebulantin with a concentration of 14.1±2.4 μM.

9. The method of claim 1 , wherein the Gram-negative pathogen is V. ordalii and the first antimicrobial agent is cebulantin with a concentration of 27.0 ±5.4 μM.

10. The method of claim 1 , wherein the Gram-negative pathogen is V. anguillarum and the first antimicrobial agent is cebulantin with a concentration of 29.1±8.2 μM.

11. The method of claim 1 , wherein the Gram-negative pathogen is P. aeruginosa and the first antimicrobial agent is cebulantin with a concentration of 47.0±11.4 μM.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 6, 2021
From: PRINCETON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 054907/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2020
From: SEYEDSAYAMDOST, MOHAMMAD R; MOON, KYUHO
To: THE TRUSTEES OF PRINCETON UNIVERSITY
Reel/Frame 054723/0215 →
Continuity (2)
Provisional Application 62938531 · Nov 21, 2019
Related Publication 20210156840A1 · May 27, 2021
References Cited (37)
Miller et al (1963), Isolation and Characterization of Antibiotic MSD-92, A Pyrimidotriazine antibiotic. Antimicrobial Agents and Chemotherapy, 161, 58-62 (Year: 1963). [cited by examiner]
Taylor, E. C., & Sowinski, F. (1975). Synthesis of the pyrimido [5, 4-e]-as-triazine antibiotics fervenulin and 2-methylfervenulone. The Journal of Organic Chemistry, 40(16), 2321-2329. (Year: 1975). [cited by examiner]
Moon, K., Xu, F., Zhang, C., & Seyedsayamdost, M. R. (2019). Bioactivity-HiTES unveils cryptic antibiotics encoded in actinomycete bacteria. ACS chemical biology, 14(4), 767-774. (Year: 2019). [cited by examiner]
Genilloud, O. (2019). Natural products discovery and potential for new antibiotics. Current opinion in microbiology, 51, 81-87. (Year: 2019). [cited by examiner]
“Moon 2019a”: Moon, K., Xu, F., Zhang, C., & Seyedsayamdost, M. R. (2019). Bioactivity-HiTES unveils cryptic antibiotics encoded in actinomycete bacteria. ACS chemical biology, 14(4), 767-774. Additional supplemental in… [cited by examiner]
“Moon 2019b”: Moon, K., Xu, F., & Seyedsayamdost, M. R. (2019). Cebulantin, a cryptic lanthipeptide antibiotic uncovered using bioactivity-coupled HiTES. Angewandte Chemie International Edition, 58(18), 5973-5977. (Year… [cited by examiner]
Ansel, H. C., Norred, W. P., & Roth, I. L. (1969). Antimicrobial activity of dimethyl sulfoxide against [cited by examiner]
Bakalar, N. (2016). Earth may be home to a trillion species of microbes. New York Times. (Year: 2016). [cited by examiner]
Rogers, Kara. “Gram-negative bacterium”. Encyclopedia Britannica, Jun. 4, 2024, https://www.britannica.com/science/Gram-negative-bacterium. Accessed Jun. 26, 2024. (Year: 2024). [cited by examiner]
Breijyeh, Z., Jubeh, B., & Karaman, R. (2020). Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules, 25(6), 1340. (Year: 2020). [cited by examiner]
Ayala, A.J., Ogbunugafor, C.B. (2023). When Vibrios Take Flight: A Meta-Analysis of Pathogenic [cited by examiner]
Gxalo O, Digban TO, Igere BE, Olapade OA, Okoh AI, Nwodo UU. Virulence and Antibiotic Resistance Characteristics of Vibrio Isolates From Rustic Environmental Freshwaters. Front Cell Infect Microbiol. Aug. 19, 2021;11:73… [cited by examiner]
Clardy et al., “New antibiotics from bacterial natural products”, Nature Biotechnology, vol. 24, No. 12, pp. 1541-1550. Dec. 2006. [cited by applicant]
Earl et al., “Discovery of human cell selective effector molecules using single cell multiplexed activity metabolomics”, Nature Communications, vol. 9, No. 39, 2018. [cited by applicant]
Okada et al., “Antibiotic dialogues: induction of silent biosynthetic gene clusters by exogenous small molecules”, FEMS Microbiology Review, vol. 41, pp. 19-33, 2017. [cited by applicant]
Zarins-Tutt et al., “Prospecting for New Bacterial Metabolites: A Glossary of Approaches for Inducing, Activating and Upregulating the Biosynthesis of Bacterial Cryptic or Silent Natural Products”, Nat. Prod. Rep. Vol. … [cited by applicant]
Seyedsayamdost et al., “High-throughput platform for the discovery of elicitors of silent bacterial gene clusters”, Proc. Natl. Acad. Sci. USA, vol. 111, No. 20, pp. 7266-7271, 2014. [cited by applicant]
Okasa et al., “Mapping the Trimethoprim-Induced Secondary Metabolome of Burkholderia thailandensis”, ACS Chem. Biol., vol. 11, No. 8, pp. 2124-2130, Aug. 19, 2016. [cited by applicant]
Xu et al., “Discovery of a Cryptic Antifungal Compound from [cited by applicant]
Moon et al., “Bioactivity-HiTES Unveils Cryptic Antibiotics Encoded in Actinomycete Bacteria”, ACS Chem. Biol. 2019, vol. 14, No. 4, pp. 767-774, DOI: 10.1021/acschembio.9b00049, Apr. 19, 2019. [cited by applicant]
Pimentel-Elardo et al., “ [cited by applicant]
Xie et al., “Saccharopolytide A, a new cyclic tetrapeptide with rare 4-hydroxy-proline moieties from the deep-sea derived actinomycete [cited by applicant]
Ruiz et al., “Chemical conditionality: a genetic strategy to probe organelle assembly”, Cell 2005, vol. 121, pp. 307-317, Apr. 22, 2005. [cited by applicant]
Repka et al., “Mechanistic Understanding of Lanthipeptide Biosynthetic Enzymes”, Chemical Reviews, vol. 117, pp. 5457-5520, 2017. [cited by applicant]
Knerr et al., “Discovery, Biosynthesis, and Engineering of Lantipeptides”, Annu. Rev. Biochem., vol. 81, pp. 479-505, 2012. [cited by applicant]
Willey et al., “Lantibiotics: Peptides of Diverse Structure and Function”, Annu. Rev. Microbiol., vol. 61, pp. 477-501, 2007. [cited by applicant]
Hudson et al., “RiPP Antibiotics: Biosynthesis and Engineering Potential”, Curr. Opin. Microbiol., vol. 45, pp. 61-69, Oct. 2018. [cited by applicant]
Mederma et al., “antiSMASH: rapid identification, annotation and analysis of secondary metabolite biosynthesis gene clusters in bacterial and fungal genome sequences”, Nucleic Acids Res., vol. 39, W339-W346, Jun. 14, 20… [cited by applicant]
Boakes et al., “Organization of the genes encoding the biosynthesis of actagardine and engineering of a variant generation system”, Molecular Microbiolgy, vol. 72, No. 5, pp. 1126-1136, 2009. [cited by applicant]
Shi et al., “Heterologous production of the lantibiotic Ala(0)actagardine in [cited by applicant]
Maier et al., “Functional characterization of different ORFs including luciferase-like monooxygenase genes from the mensacarcin gene cluster”, ChemBioChem, vol. 16, pp. 1175-1182, 2015. [cited by applicant]
Hetrick et al., “Development and Application of Yeast and Phage Display of Diverse Lanthipeptides”, ACS Cent. Sci., vol. 4, pp. 458-467, 2018. [cited by applicant]
Hetrick et al., “Ribosomally synthesized and post-translationally modified peptide natural product discovery in the genomic era”, Curr. Opin. Chem. Biol., vol. 38, pp. 36-44, Jun. 2017. [cited by applicant]
Gibson et al., “Small Biomolecules for Big Applications”, ACS Cent. Sci., vol. 4, pp. 437-439, 2018. [cited by applicant]
Craney et al., “Chemical Perturbation of Secondary Metabolism Demonstrates Important Links to Primary Metabolism”, Chemistry & Biology, vol. 19, pp. 1020-1027, Aug. 24, 2012. [cited by applicant]
Pimentel-Elardo et al., “Activity-Independent Discovery of Secondary Metabolites Using Chemical Elicitation and Cheminformatic Inference”, ACS Chem. Biol., vol. 10, pp. 2616-2623, 2015. [cited by applicant]
Xu et al., “A Genetics-Free Method for High-Throughput Discovery of Cryptic Microbial Metabolites”, Nat. Chem. Biol., vol. 15, No. 2, pp. 161-168, Feb. 2019. [cited by applicant]